News & Updates

New drug applications approved by US FDA as of 1-15 October 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

New drug applications approved by US FDA as of 16-31 October 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

The WAVE* trial demonstrates the superiority of the Wrapsody Cell–Impermeable Endoprosthesis (CIE) to percutaneous transluminal angioplasty (PTA) in haemodialysis patients who experience stenosis in their venous outflow circuit.

Macrolide resistance mutations (MRMs) were detected in more than 40 percent of Mycoplasma (M.) genitalium infections among individuals aged 14-59 years in the US in 2017-2018, representing approximately 1.4 million macrolide-resistant infections.

A phase II trial has demonstrated the safety and tolerability of combination treatment with intravesical cabazitaxel, gemcitabine, and cisplatin in patients with nonmuscle-invasive bacillus Calmette-Guérin (BCG)‒unresponsive urothelial carcinoma of the bladder.

Increased prostate volume in patients with low-grade prostate cancer on active surveillance appears to contribute to reduced risks of grade progression (GP) and receipt of definitive prostate cancer treatment, suggests a study.

In patients with locally advanced or metastatic urothelial cancer, enfortumab vedotin (EV)-induced cutaneous adverse events (cAEs) are associated with improved survival outcomes, according to a retrospective study.

High intake of saturated and animal fats following a diagnosis of nonmetastatic prostate cancer is associated with increased mortality from cardiovascular disease and other cancers, according to a study. But the good news is that replacing saturated and animal fats with healthier plant-based fats may improve survival outcomes.